Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

Inclusion Criteria: Subject is healthy, as determined by medical history. Subject is between the ages of 7 and 15 years (not yet 16 years). For subjects who participated in Study 603-02, subject previously received one dose of Menactra® vaccine or Menomune®-A/C/Y/W-135 vaccine. The date of vaccination during Study 603-02 will have occurred 5 years ± 6 months before the collection of the blood sample obtained for Study MTA23. A negative urine pregnancy test is required for menstruating female subjects. Parent/legal guardian has signed an Institutional Review Board (IRB)-approved informed consent form and subject has signed an IRB-approved assent form. Exclusion Criteria: Subjects who participated in sanofi pasteur Study MTA17 Stage I (a subset of subjects from Study 603-02 who had been recruited for the follow-up challenge study) History of documented invasive meningococcal disease Received any other meningococcal vaccine Received any vaccine in the 28-day period prior to enrollment Received antibiotic therapy within the 72 hours prior to collection of a blood sample Actively enrolled or scheduled to be enrolled in another clinical study Serious chronic disease (i.e., cardiac, renal, neurologic, rheumatologic, metabolic, gastrointestinal, psychiatric, or other organ system) Known or suspected impairment of immunologic function Acute medical illness with or without fever within 72 hours or an oral temperature ≥ 100.4°F (≥ 38.0°C) at the time of inclusion Scheduled to receive any vaccination in the 7-day or 14-day period after enrollment Administration of immune globulin, other blood products, or corticosteroid within 8 weeks (56 days) of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. Personal of family history of Guillain-Barres Syndrome Suspected or known hypersensitivity to any of the vaccine components Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures Any condition which, in the opinion of the investigator, would pose a health risk to the participant.